Specialty Pharmacy Billing: Medical vs Pharmacy Benefit, Buy-and-Bill, and Hidden Markups
Specialty drugs now account for over 55% of total drug spending in the United States, yet fewer than 2% of patients use them. If you or a family member takes an infused biologic, an injectable, or any drug that costs thousands per dose, you are navigating one of the most complex (and most profitable) corners of healthcare billing. This guide breaks down how the system works, where the hidden markups are, and how to fight back.
Specialty Drugs: 2% of Patients, 55% of Drug Spending
The average annual cost of a specialty drug exceeded $100,000 in 2025. The same drug can cost you $50 or $5,000 depending on how it is billed, where you receive it, and which benefit channel your insurer uses. Most patients never realize they have options. Understanding these billing mechanics can save you thousands per year.
Bill Defense Service
Get expert help fighting specialty drug overcharges.
Copay Accumulator Trap
How insurers steal your copay card savings.
Lower Prescription Costs
12 strategies for reducing what you pay at the pharmacy.
What You Will Learn
1. The Two Benefit Channels: Medical vs Pharmacy Benefit
Every specialty drug is billed through one of two channels, and the channel determines almost everything about what you pay. Most patients never think about this distinction, but it is one of the most important variables in specialty drug costs.
Pharmacy Benefit
- Drugs you pick up at a retail or specialty pharmacy
- Processed through a pharmacy benefit manager (PBM) like Express Scripts, CVS Caremark, or OptumRx
- Cost sharing: copay ($50 to $150) or coinsurance (25% to 33%) on the drug cost alone
- Self-administered injectables (like Humira pens) usually go through this channel
- Separate deductible from your medical plan in many cases
Medical Benefit
- Drugs administered in a doctor’s office, hospital, or infusion center
- Billed as a medical claim under Part B (Medicare) or your medical insurance
- Cost sharing: coinsurance (often 20%) on the total claim, including drug, administration, and facility fees
- Infused biologics (like Remicade, Keytruda) typically go through this channel
- Uses J-codes (HCPCS codes) for billing each drug
Why This Matters: A $4,950 Difference for the Same Drug
Consider a patient receiving a biologic infusion that costs $10,000 per treatment. Here is how the same drug can produce wildly different bills depending on the benefit channel:
Pharmacy Benefit (specialty pharmacy)
Drug cost: $10,000
Copay: $50 (flat copay tier)
Patient pays: $50
Medical Benefit (hospital outpatient)
Drug cost: $10,000 + $2,500 facility fee + $500 admin fee = $13,000
Coinsurance: 20% of $13,000
Patient pays: $2,600 (before deductible)
These numbers are illustrative. Your actual costs depend on your plan design, deductible status, and negotiated rates. But the difference between channels is real and often this dramatic.
Some drugs can be billed through either channel. For example, certain biologics are available as both an infusion (medical benefit) and a self-injectable (pharmacy benefit). If your drug has both options, ask your doctor and insurer which channel will cost you less. Some insurers have “benefit channel management” programs that automatically route drugs to the cheaper channel. Others do not, and the default routing can cost you thousands.
Action Step: Ask About Benefit Channel Options
Before starting any specialty drug, call your insurer and ask: “Is this drug covered under my pharmacy benefit, my medical benefit, or both? What is my cost-sharing under each?” If the drug is available in both an infused and self-injectable form, ask your doctor whether the self-injectable version is clinically appropriate. The savings can be substantial.
2. Buy-and-Bill: How Providers Profit from Expensive Drugs
The buy-and-bill model is one of the most consequential (and least understood) billing structures in healthcare. Here is how it works: a doctor or hospital purchases a specialty drug at wholesale cost, administers it to the patient, and then bills the insurer at a marked-up rate. The spread between the purchase price and the reimbursement rate is profit.
The Buy-and-Bill Markup Chain
Provider buys drug at wholesale
A physician or hospital purchases the drug from a wholesaler or directly from the manufacturer. Volume discounts and group purchasing organization (GPO) contracts can lower the acquisition cost further.
Drug is administered to the patient
The provider stores, prepares, and infuses or injects the drug. They also bill an administration fee (CPT code 96413 for the first hour of infusion, for example).
Provider bills insurer at ASP + markup
Medicare reimburses at Average Sales Price (ASP) plus 6%. Commercial insurers often pay ASP plus 20% to 30%, or even higher under some contracts. The gap between acquisition cost and reimbursement is the provider’s margin.
The Perverse Incentive: More Expensive Drug = More Profit
Because the markup is a percentage of the drug price, providers earn more money when they prescribe a more expensive drug. Consider this real-world example with Remicade (brand) vs Inflectra (biosimilar):
Remicade (brand)
ASP per infusion: ~$4,500
Medicare reimbursement (ASP+6%): ~$4,770
Provider acquisition cost: ~$3,800
Provider profit: ~$970 per infusion
Inflectra (biosimilar)
ASP per infusion: ~$2,800
Medicare reimbursement (ASP+6%): ~$2,968
Provider acquisition cost: ~$2,500
Provider profit: ~$468 per infusion
The provider earns roughly twice as much per infusion by choosing the brand over the biosimilar. For a patient getting infusions every 8 weeks, that is over $3,000 per year in additional provider profit, and higher cost-sharing for the patient. Numbers are illustrative based on published ASP data.
The Inflation Reduction Act (IRA) included provisions to address some of these incentives for Medicare patients. Starting in 2025, Medicare began paying for biosimilars at ASP plus 8% (instead of ASP plus 6%) for the first five years after launch, creating a temporary incentive for providers to switch to biosimilars. However, buy-and-bill incentives remain largely intact for commercial insurance, where markups are often much higher.
For patients, the takeaway is straightforward: if your doctor is recommending a brand biologic and a biosimilar exists, ask why. In most cases, the biosimilar is clinically equivalent and significantly cheaper. If your doctor insists on the brand, ask whether the buy-and-bill margin is influencing that decision. You have the right to request the more affordable option.
Getting Charged Too Much for Infusion Drugs?
CareRoute’s Bill Defense team audits specialty drug bills for hidden markups, incorrect J-codes, and inflated facility fees. You pay nothing unless we save you money.
3. White Bagging vs Brown Bagging: Insurer Supply Chain Control
As buy-and-bill costs have risen, insurers have developed two strategies to remove the provider from the drug supply chain. Both are designed to eliminate the buy-and-bill markup, but they create new trade-offs for patients.
White Bagging
The insurer’s specialty pharmacy dispenses the drug and ships it directly to the doctor’s office. The doctor administers it but did not purchase it.
Brown Bagging
The patient picks up the drug from a specialty pharmacy and physically brings it to the doctor’s office for administration.
State Legislation on White and Brown Bagging
Several states have passed or are considering laws that restrict or ban white bagging and brown bagging mandates. These laws typically give providers the right to refuse to administer drugs they did not purchase and store. If your insurer mandates white bagging or brown bagging and your provider objects, check your state’s laws. You may have grounds to appeal for an exception.
Both strategies are fundamentally about cost control for insurers. They can save patients money in some cases, but they also introduce logistical complexity and safety risks. If your insurer requires white bagging or brown bagging, ask about the specific cost impact. Sometimes the savings are meaningful. Other times, the insurer captures all the savings and your cost-sharing stays the same.
4. Biosimilar Switch Rights and Savings
Biosimilars are the single biggest opportunity for specialty drug savings. An FDA-approved biosimilar is a biologic drug that is highly similar to an already-approved reference product, with no clinically meaningful differences in safety or effectiveness. Think of them as the biologic equivalent of generic drugs, though the science behind them is more complex.
Biosimilar Savings: 15% to 40% Less Than the Reference Biologic
Interchangeable vs Non-Interchangeable Biosimilars
This is an important distinction. An interchangeable biosimilar has met a higher FDA standard and can be substituted at the pharmacy level without a new prescription from your doctor. This is similar to how a pharmacist can give you generic atorvastatin instead of brand Lipitor. A non-interchangeable biosimilar requires your doctor to write a new prescription specifically for the biosimilar product.
Cyltezo was the first interchangeable biosimilar approved in the U.S. (for Humira). Several others have followed. As more biosimilars gain interchangeability status, pharmacists will be able to switch patients automatically, accelerating adoption and savings.
State Substitution Laws: What to Know
All 50 states have enacted biosimilar substitution laws, but the details vary:
- Most states allow pharmacists to substitute an interchangeable biosimilar unless the prescriber writes “dispense as written” or “brand medically necessary”
- Many states require the pharmacist to notify the prescriber within a set number of days after substitution
- Some states require patient notification or consent before substitution
- Non-interchangeable biosimilars always require a new prescription
How to Talk to Your Doctor About Biosimilars
Ask your doctor directly: “Is there a biosimilar available for my medication, and would it be clinically appropriate for me?” If your doctor is hesitant, ask for the specific clinical reason. In most cases, switching from a reference biologic to its biosimilar is safe and straightforward. If your doctor insists on the brand, ask whether you can do a trial period on the biosimilar. Also check whether your insurer offers a lower cost-sharing tier for biosimilars, which many now do to encourage switching.
5. Site-of-Care Optimization: Where You Get Treated Matters
For infused specialty drugs, the location where you receive treatment can be more important than the drug itself when it comes to your bill. Hospital outpatient departments charge facility fees that can double or triple the total cost of an infusion compared to a freestanding center or home infusion.
Cost Comparison by Infusion Site (Illustrative)
For a biologic infusion with a $5,000 drug cost:
Hospital Outpatient Department
Drug ($5,000) + facility fee ($2,000 to $4,000) + admin fee ($500)
$7,500 to $9,500
Freestanding Infusion Center
Drug ($5,000) + admin fee ($200 to $400), no facility fee
$5,200 to $5,400
Home Infusion
Drug ($5,000) + nursing visit ($150 to $300), no facility fee
$5,150 to $5,300
If your coinsurance is 20%, the hospital outpatient bill costs you $1,500 to $1,900. The home infusion bill costs you $1,030 to $1,060. That is a savings of $470 to $840 per treatment, or $3,000 to $5,000 per year on a biweekly infusion schedule.
Home infusion is the fastest-growing segment of specialty drug delivery. For many conditions (rheumatoid arthritis, Crohn’s disease, multiple sclerosis, primary immunodeficiency), home infusion is clinically appropriate and preferred by patients for convenience. Major insurers including UnitedHealthcare, Aetna, and Cigna have launched site-of-care management programs that steer patients away from hospital outpatient settings and toward freestanding centers or home infusion.
How to Request a Site-of-Care Change
- 1.Call your insurer and ask if they have a site-of-care management or optimization program
- 2.Ask your doctor to confirm that home infusion or a freestanding center is clinically appropriate for your treatment
- 3.Request a cost comparison from your insurer showing your out-of-pocket cost at each site option
- 4.If your insurer does not offer a formal program, ask for a prior authorization for the alternative site
- 5.If denied, file an appeal citing the cost savings and clinical equivalence
Overpaying for Specialty Drugs?
Our Bill Defense team has helped patients save thousands by identifying site-of-care overcharges, buy-and-bill markups, and benefit channel errors. We handle the fight so you can focus on treatment.
6. Specialty Tier Copays and the Copay Assistance Trap
Most health plans organize drugs into tiers, with generic drugs on Tier 1 (lowest cost) and specialty drugs on Tier 4 or Tier 5 (highest cost). Unlike lower tiers that charge a flat copay ($10, $30, or $50), specialty tiers almost always use percentage coinsurance, typically 25% to 33% of the drug cost.
The Math on Specialty Tier Coinsurance
A specialty drug that costs $8,000 per month with 25% coinsurance means you owe $2,000 per fill.
At 33% coinsurance, you owe $2,640 per fill.
Over a year (12 fills), that is $24,000 to $31,680 before reaching any out-of-pocket maximum. Most patients hit their annual out-of-pocket maximum within the first 1 to 3 fills, but that maximum is itself $9,450 for an individual in 2026 (the ACA maximum for marketplace plans).
Manufacturer Copay Assistance Programs
Nearly every expensive specialty drug comes with a manufacturer-sponsored copay assistance card. These cards can cover $5,000 to $20,000 per year in out-of-pocket costs. They exist because the drug manufacturer wants you to stay on their product, and they know that high coinsurance drives patients to switch or abandon treatment.
However, there is a critical trap: copay accumulator programs. About 80% of commercial insurers now use copay accumulators that do not count manufacturer copay card payments toward your deductible or out-of-pocket maximum. When the copay card runs out (usually mid-year), you face the full cost of the drug with no progress toward your deductible.
Read the Full Guide on Copay Accumulators
We wrote a detailed guide covering copay accumulator detection, state bans, and step-by-step defense strategies. If you use a manufacturer copay card for any specialty drug, this is essential reading.
Read: Copay Accumulator Programs GuidePatient Assistance Programs (PAPs) for Specialty Drugs
If you are uninsured, underinsured, or cannot afford your specialty drug even with insurance, most manufacturers offer Patient Assistance Programs that provide the drug for free or at very low cost. Eligibility varies but is often based on income (typically under 400% to 600% of the federal poverty level). Some programs have no income limit for uninsured patients.
Independent charitable foundations (like the Patient Access Network Foundation, HealthWell Foundation, and the Assistance Fund) also provide copay assistance for specific diseases. These foundation grants are separate from manufacturer copay cards and typically do count toward your deductible, making them a better option if your plan has a copay accumulator.
Frequently Asked Questions
What is the difference between medical benefit and pharmacy benefit for specialty drugs?▼
Pharmacy benefit covers drugs you pick up at a pharmacy. These are processed through a pharmacy benefit manager (PBM) and typically have a copay or coinsurance on the drug cost alone. Medical benefit covers drugs administered in a doctor’s office, hospital, or infusion center. These are billed as medical claims and can include facility fees and administration charges. The same drug can cost dramatically different amounts depending on which benefit it goes through.
What is buy-and-bill and why does it make drugs more expensive?▼
Buy-and-bill is when a doctor or hospital purchases a specialty drug at wholesale and bills the insurer at a markup (ASP plus 6% for Medicare, often much higher for commercial insurance). Because the markup is a percentage of the drug price, providers earn more when they prescribe more expensive drugs. This creates a financial incentive to choose a brand biologic over a cheaper biosimilar, even when they are clinically equivalent.
Can I switch from a brand biologic to a biosimilar?▼
Yes. If an FDA-approved interchangeable biosimilar exists for your drug, a pharmacist can substitute it without a new prescription (similar to generic substitution). For non-interchangeable biosimilars, your doctor needs to write a new prescription. Biosimilars typically cost 15% to 40% less than the reference biologic. As of 2026, there are 8 or more Humira biosimilars, several Remicade biosimilars, and biosimilars for Herceptin and Avastin.
What is white bagging and is it safe?▼
White bagging is when your insurer’s specialty pharmacy ships a drug directly to your doctor’s office instead of letting the doctor buy it. It can lower costs by eliminating the buy-and-bill markup. However, there are concerns about treatment delays if shipments are late, drug integrity during transit, and provider liability. Several states have passed laws giving providers the right to refuse white-bagged drugs. If your insurer mandates it, ask about the specific cost impact to you and whether exceptions are available.
How much can I save by switching to home infusion?▼
Home infusion eliminates the hospital facility fee, which can be $2,000 to $4,000 per visit. For a patient on a biweekly infusion schedule with 20% coinsurance, switching from hospital outpatient to home infusion can save $3,000 to $5,000 per year in out-of-pocket costs. Home infusion also saves you time and travel. Ask your insurer and doctor whether home infusion is an option for your specific treatment.
What is a J-code and why should I check it on my bill?▼
A J-code is a billing code used for injectable and infusible drugs under the medical benefit. Each drug has its own J-code (for example, J1745 for Remicade). Billing errors with J-codes are surprisingly common. If the wrong J-code is used, you could be charged for a more expensive drug than you received. Always check your Explanation of Benefits (EOB) to confirm the correct drug name and J-code appear. If something looks wrong, call your insurer to dispute it.
Will my copay card payments count toward my deductible?▼
Maybe not. About 80% of commercial health plans now use copay accumulator programs that do not count manufacturer copay card payments toward your deductible or out-of-pocket maximum. Check your plan documents for language about “copay adjustment programs” or “third-party payment exclusions.” Review your EOB to see whether copay card payments are being credited toward your deductible. If they are not, read our copay accumulator guide for defense strategies.
Are specialty drugs cheaper through the pharmacy benefit or medical benefit?▼
It depends on your plan design. Pharmacy benefit typically has more predictable cost-sharing (a set copay or coinsurance on the drug cost alone). Medical benefit can include facility fees, provider markups, and coinsurance on the entire claim. However, if you have already met your medical deductible, the medical benefit might be cheaper. The best approach is to call your insurer before starting treatment and ask them to compare your cost under each benefit channel.
Related Resources
Lower Your Prescription Costs
12 proven strategies to reduce what you pay for medications, from patient assistance programs to generic switches.
Read guideCopay Accumulator Programs
How 80% of insurers redirect your copay card payments, and what you can do about it.
Read guideAppeal a Medication Denial
Step-by-step guide to overturning denied prescriptions and prior authorization rejections.
Read guide340B Drug Pricing
How safety-net hospitals get drugs at steep discounts, and whether those savings reach patients.
Read guideSpecialty Drug Bills Are Complicated. We Make Them Fair.
CareRoute’s Bill Defense team specializes in specialty pharmacy billing. We audit for buy-and-bill markups, incorrect J-codes, inflated facility fees, and benefit channel errors. We negotiate with providers and insurers on your behalf. You pay nothing unless we save you money.
Get Started with Bill Defense